Article: [Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer:  A Case Report and Literature Review]

Immune checkpoint inhibitors (ICIs) show unique advantages in the treatment of lung cancer, making the treatment of lung cancer enter the era of immunotherapy, but ICIs will also have adverse reactions, and the incidence of immune-induced hematological toxicity is not very high. Immunotherapy-induced thrombocytopenia is a rare adverse event.We report one case of thrombocytopenia induced by ICIs and review the literature on thrombocytopenia associated with ICIs and discuss the clinical features, possible mechanisms, and optimal treatment.  .

Citing Articles

Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis.

Wang S, Cai M, Xiong Y, Guo T, Niu X, Chen Y Eur J Clin Pharmacol. 2025; .

PMID: 39841181 DOI: 10.1007/s00228-025-03803-z.

References

1.

Weber J, Yang J, Atkins M, Disis M . Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015; 33(18):2092-9. PMC: 4881375. DOI: 10.1200/JCO.2014.60.0379. View

2.

Khorasanchi A, Keresztes R . Severe immune thrombocytopenia induced by a single dose of nivolumab in a patient with advanced non-small cell lung cancer. Clin Pract. 2020; 10(2):1249. PMC: 7308713. DOI: 10.4081/cp.2020.1249. View

3.

Mori H, Sakai C, Iwai M, Sasaki Y, Gomyo T, Toyoshi S . Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer. Respir Med Case Rep. 2019; 28:100871. PMC: 6557745. DOI: 10.1016/j.rmcr.2019.100871. View

4.

Wu D, Liu Y, Pang N, Sun M, Wang X, Haridia Y . PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients. Medicine (Baltimore). 2019; 98(43):e17608. PMC: 6824755. DOI: 10.1097/MD.0000000000017608. View

5.

Birtas Atesoglu E, Tarkun P, Terzi Demirsoy E, Geduk A, Mehtap O, Batman A . Soluble Programmed Death 1 (PD-1) Is Decreased in Patients With Immune Thrombocytopenia (ITP): Potential Involvement of PD-1 Pathway in ITP Immunopathogenesis. Clin Appl Thromb Hemost. 2014; 22(3):248-51. DOI: 10.1177/1076029614562952. View

6.

Shiuan E, Beckermann K, Ozgun A, Kelly C, McKean M, McQuade J . Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017; 5:8. PMC: 5319013. DOI: 10.1186/s40425-017-0210-0. View

7.

Hasegawa T, Ozaki Y, Inoue T, Watanabe Y, Fukuhara M, Yamaura T . Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature. J Med Case Rep. 2019; 13(1):316. PMC: 6813076. DOI: 10.1186/s13256-019-2245-y. View

8.

Fang W, Yang Y, Ma Y, Hong S, Lin L, He X . Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018; 19(10):1338-1350. DOI: 10.1016/S1470-2045(18)30495-9. View

9.

Karakas Y, Yuce D, Kilickap S . Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient. Oncol Res Treat. 2017; 40(10):621-622. DOI: 10.1159/000477968. View

10.

Jotatsu T, Oda K, Yamaguchi Y, Noguchi S, Kawanami T, Kido T . Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. Immunotherapy. 2017; 10(2):85-91. DOI: 10.2217/imt-2017-0100. View

11.

Tokumo K, Masuda T, Miyama T, Miura S, Yamaguchi K, Sakamoto S . Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma. Lung Cancer. 2018; 119:21-24. DOI: 10.1016/j.lungcan.2018.02.018. View

[Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer: A Case Report and Literature Review]

[Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer:  A Case Report and Literature Review]